Back to Journals » Drug Design, Development and Therapy » Volume 13

Endostatin attenuates PDGF-BB- or TGF-β1-induced HSCs activation via suppressing RhoA/ROCK1 signal pathways [Erratum]

Authors Ren H, Li Y, Chen Y, Wang L

Received 23 January 2019

Accepted for publication 23 January 2019

Published 31 January 2019 Volume 2019:13 Pages 499—500

DOI https://doi.org/10.2147/DDDT.S202671


Ren H, Li Y, Chen Y, Wang L. Drug Des Devel Ther. 2019; 13:285–290.

On page 289, Figure 4 and Notes should read as follows:

Figure 4 Endostatin inhibits the expression of α-SMA, RhoA, and ROCK1 at mRNA level.
Notes: Transcript levels of α-SMA, RhoA, and ROCK1 were analyzed by RT-PCR (AC). Endostatin significantly suppressed the expressions of α-SMA, RhoA, and ROCK1 at mRNA level in HSC-T6 cells. Data are expressed as mean ± SD. *P<0.05, **P<0.01 (n=3 per group).
Abbreviations: α-SMA, α-smooth muscle actin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSC, hepatic stellate cell; RhoA, ras homolog gene family, member A; ROCK1, Rho-associated protein kinase 1; RT-PCR, real-time PCR.

Read the original article
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]